0001209191-17-013565.txt : 20170222
0001209191-17-013565.hdr.sgml : 20170222
20170222213542
ACCESSION NUMBER: 0001209191-17-013565
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170217
FILED AS OF DATE: 20170222
DATE AS OF CHANGE: 20170222
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OncoCyte Corp
CENTRAL INDEX KEY: 0001642380
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 271041563
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
BUSINESS PHONE: 510-775-0515
MAIL ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HESTERBERG LYNDAL K.
CENTRAL INDEX KEY: 0001689836
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37648
FILM NUMBER: 17630584
MAIL ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-02-17
0
0001642380
OncoCyte Corp
OCX
0001689836
HESTERBERG LYNDAL K.
1010 ATLANTIC AVENUE
SUITE 102
ALAMEDA
CA
94501
0
1
0
0
Sr VP, Research & Development
Option to Purchase Common Stock
4.70
2017-02-17
4
A
0
14400
0.00
A
2027-02-16
Common Stock
14400
14400
D
Option to Purchase Common Stock
4.05
2026-10-31
Common Stock
125000
125000
D
Option to Purchase Common Stock
3.06
2026-02-15
Common Stock
25000
25000
D
One quarter of the options shall vest on February 16, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
One quarter of the options shall vest on October 31, 2017, subject to the completion of 12 months of continuous employment from the date of grant on November 1, 2016, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
One quarter of the options vested on February 15, 2017 and one quarter shall vest on February 15, 2018, and the balance shall vest upon the attainment of certain product development milestones, in each case depending upon continuous employment by the Company.
/s/Lyndal K. Hesterberg
2017-02-22